CA2065346A1 - Recepteurs .alpha. et .beta. de facteur de necrose tumorale - Google Patents

Recepteurs .alpha. et .beta. de facteur de necrose tumorale

Info

Publication number
CA2065346A1
CA2065346A1 CA002065346A CA2065346A CA2065346A1 CA 2065346 A1 CA2065346 A1 CA 2065346A1 CA 002065346 A CA002065346 A CA 002065346A CA 2065346 A CA2065346 A CA 2065346A CA 2065346 A1 CA2065346 A1 CA 2065346A1
Authority
CA
Canada
Prior art keywords
necrosis factor
tumor necrosis
receptors
beta
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002065346A
Other languages
English (en)
Other versions
CA2065346C (fr
Inventor
Craig A. Smith
Raymond G. Goodwin
M. Patricia Beckmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002485553A priority Critical patent/CA2485553A1/fr
Publication of CA2065346A1 publication Critical patent/CA2065346A1/fr
Application granted granted Critical
Publication of CA2065346C publication Critical patent/CA2065346C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002065346A 1989-09-05 1990-07-17 Recepteurs .alpha. et .beta. de facteur de necrose tumorale Expired - Lifetime CA2065346C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002485553A CA2485553A1 (fr) 1989-09-05 1990-07-17 Recepteurs .alpha. et .beta. de facteur de necrose tumorale

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US40324189A 1989-09-05 1989-09-05
US403,241 1989-09-05
US40537089A 1989-09-11 1989-09-11
US405,370 1989-09-11
US42141789A 1989-10-13 1989-10-13
US421,417 1989-10-13
PCT/US1990/004001 WO1991003553A1 (fr) 1989-09-05 1990-07-17 RECEPTEURS DES FACTEURS NECROSE TUMORALE α et $g(b)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002485553A Division CA2485553A1 (fr) 1989-09-05 1990-07-17 Recepteurs .alpha. et .beta. de facteur de necrose tumorale

Publications (2)

Publication Number Publication Date
CA2065346A1 true CA2065346A1 (fr) 1991-03-06
CA2065346C CA2065346C (fr) 2005-03-29

Family

ID=46201946

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002065346A Expired - Lifetime CA2065346C (fr) 1989-09-05 1990-07-17 Recepteurs .alpha. et .beta. de facteur de necrose tumorale
CA002485553A Expired - Lifetime CA2485553A1 (fr) 1989-09-05 1990-07-17 Recepteurs .alpha. et .beta. de facteur de necrose tumorale

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002485553A Expired - Lifetime CA2485553A1 (fr) 1989-09-05 1990-07-17 Recepteurs .alpha. et .beta. de facteur de necrose tumorale

Country Status (3)

Country Link
AU (1) AU630497B2 (fr)
CA (2) CA2065346C (fr)
WO (1) WO1991003553A1 (fr)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0393438T3 (da) 1989-04-21 2005-05-30 Amgen Inc TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
EP0939121B2 (fr) * 1989-09-12 2007-12-26 AHP Manufacturing B.V. Protéines liant le TNF
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
ES2123515T3 (es) * 1991-03-29 1999-01-16 Immunex Corp Antagonistas de citoquinas a base de proteinas virales aisladas.
WO1993006128A1 (fr) * 1991-09-16 1993-04-01 Peptide Technology Limited Peptides antagonistes du facteur de necrose tumorale
WO1993007863A1 (fr) * 1991-10-15 1993-04-29 Mullarkey Michael F Procedes et compositions servant a traiter des reactions allergiques
AU670125B2 (en) * 1992-09-15 1996-07-04 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
NZ263102A (en) * 1993-03-19 1997-05-26 Immunex Corp Pharmaceutical compositions comprising a ligand protein such as interleukin-4 and a soluble receptor protein that binds thereto
NZ278607A (en) * 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
SK288144B6 (sk) 1996-02-09 2013-12-02 Amgen, Inc. Pharmaceutical composition and its use for treating inflammatory diseases
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
ES2312179T3 (es) 1996-12-06 2009-02-16 Amgen Inc. Terapia combinada que utiliza un inhibidor del il-1 para el tratamiento de enfermedades mediadas por el il-1.
WO1998024463A2 (fr) 1996-12-06 1998-06-11 Amgen Inc. Therapie combinatoire utilisant une proteine de liaison du facteur de necrose tumorale (tnf) dans le traitement de maladies induites par le tnf
US6893838B1 (en) 1998-04-07 2005-05-17 Genetics Institute Llc DADD, death activator death domain protein
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20080213778A1 (en) 1998-12-30 2008-09-04 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
US7041474B2 (en) * 1998-12-30 2006-05-09 Millennium Pharmaceuticals, Inc. Nucleic acid encoding human tango 509
DE60021373T2 (de) * 1999-05-10 2006-04-27 Chugai Seiyaku K.K. Verfahren der zellkultivierung
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
DK2990420T3 (en) 2000-05-26 2017-04-03 Immunex Corp USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF
EP2295081B1 (fr) 2001-06-26 2018-10-31 Amgen Inc. Anticorps OPGL
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
WO2004009776A2 (fr) 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. Traitement de troubles en relation avec le tnf$g(a)
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
NZ595225A (en) 2005-05-16 2013-05-31 Abbott Biotech Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
CN103336129A (zh) 2005-11-01 2013-10-02 阿布维生物技术有限公司 使用生物标志物诊断强直性脊柱炎的方法和组合物
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
EP2666479A3 (fr) 2006-04-10 2014-03-26 Abbott Biotechnology Ltd Utilisations et compositions pour le traitement de l'arthrite rhumatoïde juvénile
WO2008063213A2 (fr) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Compositions destinées au traitement de la polyarthrite psoriasique et leurs applications
CA2564435A1 (fr) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methodes de controle et de traitement des troubles intestinaux
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
MX2008016335A (es) 2006-06-30 2009-01-21 Abbott Biotech Ltd Dispositivo automatico de inyeccion.
SI2061803T2 (sl) 2006-08-28 2023-01-31 Ares Trading S.A. Postopek za čiščenje proteinov, ki vsebujejo FC
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
WO2008150491A2 (fr) 2007-05-31 2008-12-11 Abbott Laboratories Biomarqueurs prédictifs de la réactivité aux inhibiteurs tnfα dans des troubles auto-immuns
WO2008154543A2 (fr) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Procédés de traitement de l'arthrite idiopathique juvénile
US20110251099A1 (en) 2008-12-30 2011-10-13 Sudha Visvanathan SERUM MARKERS PREDICTING CLINICAL RESPONSE TO ANTI-TNFa ANTIBODIES IN PATIENTS WITH ANKYLOSING SPONDYLITIS
WO2010127146A1 (fr) 2009-04-29 2010-11-04 Abbott Biotechnology Ltd Dispositif d'injection automatique
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
US20110150891A1 (en) 2009-12-16 2011-06-23 Philip Bosch Methods of Treating Interstitial Cystitis
PH12012501364A1 (en) 2010-01-15 2012-10-22 Amgen K A Inc Antibody formulation and therapeutic regimens
JP2013518590A (ja) 2010-02-02 2013-05-23 アボツト・バイオテクノロジー・リミテツド ＴＮＦ−α阻害剤を用いる処置に対する応答性を予測するための方法および組成物
JP5809242B2 (ja) 2010-04-21 2015-11-10 アッヴィ バイオテクノロジー リミテッド 治療薬の制御送達のための装着型自動注入装置
WO2011146727A1 (fr) 2010-05-19 2011-11-24 Philip Bosch Méthodes de traitement de la cystite interstitielle
EP2575884B1 (fr) 2010-06-03 2018-07-18 AbbVie Biotechnology Ltd Utilisations et compositions pour le traitement de l'hidrosadénite (hs)
EP2490024A1 (fr) 2010-12-22 2012-08-22 Proteomika, S.L. Procédé pour optimiser le traitement de patients au moyen de médicaments biologiques
RU2727040C2 (ru) 2011-01-24 2020-07-17 Эббви Байотекнолоджи Лтд. Автоматические инъекционные устройства, имеющие наформованные поверхности захвата
CA2829773A1 (fr) 2011-03-18 2012-09-27 Abbvie Inc. Systemes, dispositifs et procedes pour assembler des dispositifs a injection automatique et des sous-ensembles leur correspondant
MX2013011263A (es) 2011-03-29 2014-03-27 Abbvie Inc Despliegue de cubierta mejorado en dispositivos de inyeccion automaticos.
ES2605817T3 (es) 2011-04-21 2017-03-16 Abbvie Inc. Dispositivo de inyección automático portátil
WO2013016220A1 (fr) 2011-07-22 2013-01-31 Amgen Inc. Récepteur a de il-il-17 requis pour biologie il-17c
JP2016511747A (ja) 2013-01-04 2016-04-21 マサチューセッツ インスティテュート オブ テクノロジー ナノ粒子表面結合に基づく薬物の組織への送達
CA2944605C (fr) 2014-03-31 2023-10-17 Kirin-Amgen, Inc. Procedes de traitement du psoriasis des ongles et du cuir chevelu
CA2970577A1 (fr) 2014-12-22 2016-06-30 Ares Trading S.A. Composition pharmaceutique liquide
EP3440113A1 (fr) 2016-04-08 2019-02-13 Gilead Sciences, Inc. Compositions et méthodes de traitement du cancer, de maladies inflammatoires et de maladies autoimmunes
WO2018106945A1 (fr) 2016-12-07 2018-06-14 Progenity Inc. Procédés, dispositifs et systèmes de détection du tractus gastro-intestinal
CN110430801B (zh) 2016-12-14 2024-04-30 比奥拉治疗股份有限公司 使用tnf抑制剂治疗胃肠道疾病
JOP20190162A1 (ar) 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
US20230312700A1 (en) 2018-06-20 2023-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
CN112654350A (zh) 2018-07-03 2021-04-13 诺华股份有限公司 使用nlrp3拮抗剂治疗对tnf抑制剂有抗性的受试者或针对所述患者选择治疗的方法
US20220387397A1 (en) 2018-10-24 2022-12-08 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
CN113015730A (zh) 2018-11-13 2021-06-22 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
EP3880666B1 (fr) 2018-11-13 2023-06-28 Novartis AG Composés et compositions destinés au traitement d'états pathologiques associés à une activité nlrp
EP3883635A1 (fr) 2018-11-19 2021-09-29 Progenity, Inc. Méthodes et dispositifs pour traiter une maladie au moyen d'une biothérapie
EP3914583A1 (fr) 2019-01-22 2021-12-01 Novartis AG Composés et compositions pour traiter des états associés à une activité de nlrp
WO2021002887A1 (fr) 2019-07-02 2021-01-07 Novartis Inflammasome Research, Inc. Antagonistes de nlrp3 ciblant l'intestin et leur utilisation en thérapie
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
IL319437A (en) 2022-09-07 2025-05-01 Mdx Man Llc Shp-1 inhibitors for treating cancer
WO2024097804A1 (fr) 2022-11-02 2024-05-10 Mdx Management Llc Combinaison d'un inhibiteur de tyrosine kinase et d'un agent pro-inflammatoire pour le traitement du cancer
AU2024239074A1 (en) 2023-03-17 2025-10-02 Mdx Management Llc Compositions and methods for ameliorating adverse effects of therapies
WO2025038745A1 (fr) 2023-08-16 2025-02-20 Mdx Management Llc Compositions et procédés pour activation de cellules immunitaires
AU2024334289A1 (en) 2023-08-25 2026-04-09 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof
WO2025188920A1 (fr) 2024-03-06 2025-09-12 Mdx Management Llc Application locale d'agents inhibant la signalisation tyrosine kinase ou shp-1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
GB8806339D0 (en) * 1988-03-17 1988-04-13 Hoffmann La Roche Monoclonal antibodies
GB8807803D0 (en) * 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product

Also Published As

Publication number Publication date
WO1991003553A1 (fr) 1991-03-21
AU630497B2 (en) 1992-10-29
CA2065346C (fr) 2005-03-29
AU6178190A (en) 1991-04-08
CA2485553A1 (fr) 1991-03-21

Similar Documents

Publication Publication Date Title
CA2065346A1 (fr) Recepteurs .alpha. et .beta. de facteur de necrose tumorale
GR3019333T3 (en) Tumor necrosis factor-alpha and -beta receptors
EP0318296A3 (fr) Récepteurs d'interleukine-1
CA2125763C (fr) Homodimere p40 de l'interleukine-12
IL98205A0 (en) Type ii interleukin-1 receptors
CA2032191A1 (fr) Expression de la proteine recombinante liant le facteur de necrose des tumeurs
CA2267670A1 (fr) Methode pour preparer des cellules humaines a facteur souches polypeptide
WO1998030694A3 (fr) RECEPTEURS 6α ET 6β DU FACTEUR DE NECROSE TUMORALE
IL83192A0 (en) Method for the preparation of proteins with factor viii activity by microbial host cells;expression vectors,host cells,antibodies
EP0243153A3 (fr) Expression de la protéine du G-CSF humain
AU9482498A (en) Interleukin-17 receptor-like protein
AU5020296A (en) C-C chemokine receptor 3: CKR-3 or EOS-l2
IL91705A0 (en) Interleukin-4 receptors,dna and expression vectors encoding them and process for producing the receptors
CA2108473A1 (fr) Structure, production et utilisation de l'hereguline
IE902158L (en) Interleukin-7 Receptors
IL88151A (en) Interleukin-7 protein, dna sequences encoding it, its preparation and compositions containing it
IL87622A0 (en) Recombinant eukaryotic cells producing interleukin-2,process and vectors for their preparation and process for the preparation of interleukin-2
IL84700A (en) Hybrid proteins,dnas coding therefor,hybrid vectors containing such dnas and hosts transformed therewith,the preparation of such hybrid proteins and pharmaceutical compositions containing them
GB2171703B (en) Expression-secretion vector for gene expression and protein secretion, recombinant dna including the vector, and method of producing proteins by use of the re
CA2051010A1 (fr) Proteine de recepteur a l'hormone-chorionique gonadotropin luteinisante humaine, adn et leur utilisation
WO1998053069A3 (fr) Recepteurs du gdnf
CA2089111A1 (fr) Agent mitogene des muscles lisses et adn isole l'encodant
CA2050477A1 (fr) Facteur de croissances des lymphocytes t

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry